Literature DB >> 19525451

Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.

Theo J M Ruers1, Bastiaan Wiering, Joost R M van der Sijp, Rudi M Roumen, Koert P de Jong, Emile F I Comans, Jan Pruim, Helena M Dekker, Paul F M Krabbe, Wim J G Oyen.   

Abstract

UNLABELLED: With the increasing possibilities for surgical treatment of colorectal liver metastases, careful selection of patients who may benefit from surgical treatment becomes critical. The addition of PET to (18)F-FDG may significantly improve conventional staging by CT. Up to now, definitive evidence that the addition of (18)F-FDG PET to conventional staging leads to superior clinical results and improved clinical management in these patients has been lacking. In this randomized controlled trial in patients with colorectal liver metastases, we investigated whether the addition of (18)F-FDG PET is beneficial and reduces the number of futile laparotomies.
METHODS: A total of 150 patients with colorectal liver metastases selected for surgical treatment by imaging with CT were randomly assigned to CT only (n = 75) or CT plus (18)F-FDG PET (n = 75). Patients were followed up for at least 3 y. The primary outcome measure was futile laparotomy, defined as any laparotomy that did not result in complete tumor treatment, that revealed benign disease, or that did not result in a disease-free survival period longer than 6 mo.
RESULTS: Patient and tumor characteristics were similar for both groups. The number of futile laparotomies was 34 (45%) in the control arm without (18)F-FDG PET and 21 (28%) in the experimental arm with (18)F-FDG PET; the relative risk reduction was 38% (95% confidence interval, 4%-60%, P = 0.042).
CONCLUSION: The number of futile laparotomies was reduced from 45% to 28%; thus, the addition of (18)F-FDG PET to the work-up for surgical resection of colorectal liver metastases prevents unnecessary surgery in 1 of 6 patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525451     DOI: 10.2967/jnumed.109.063040

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  43 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  The role of 18FDG PET/CT in the management of colorectal liver metastases.

Authors:  Alec H Engledow; James R A Skipworth; Farrokh Pakzad; Charles Imber; Peter J Ell; Ashley M Groves
Journal:  HPB (Oxford)       Date:  2011-11-14       Impact factor: 3.647

3.  Colorectal liver metastases with extrahepatic disease--a new criteria for oncologic resection?

Authors:  Terence C Chua; David L Morris
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 4.  [Importance of FDG-PET/computed tomography in colorectal cancer].

Authors:  S Kleiner; W Weber
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

5.  (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in the Management of Metastatic Colorectal Cancer: Are we there yet?

Authors:  Khalid Al-Naamani; Siham Al-Sinani
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

6.  Photons across medicine: relating optical and nuclear imaging.

Authors:  Robert Nordstrom; Simon Cherry; Ali Azhdarinia; Eva Sevick-Muraca; Henry Vanbrocklin
Journal:  Biomed Opt Express       Date:  2013-11-05       Impact factor: 3.732

7.  Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany.

Authors:  Christina Pfannenberg; Brigitte Gueckel; Lisa Wang; Sergios Gatidis; Susann-Cathrin Olthof; Werner Vach; Matthias Reimold; Christian la Fougere; Konstantin Nikolaou; Peter Martus
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

8.  Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input.

Authors:  Sudheer D Rani; Samuel T Nemanich; Nicole Fettig; Kooresh I Shoghi
Journal:  Nucl Med Biol       Date:  2013-02-28       Impact factor: 2.408

9.  Patient tailored resection planning in patients undergoing liver surgery for colorectal liver metastases; how and why should you do it?

Authors:  C S van Kessel; M S van Leeuwen; R van Hillegersberg; I H M Borel Rinkes; M A A J van den Bosch; I Q Molenaar
Journal:  J Gastrointest Surg       Date:  2013-04-25       Impact factor: 3.452

Review 10.  Surgery for colorectal liver metastases.

Authors:  J N Primrose
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.